PPAR activators and COX inhibitors selectively block cytokine-induced COX-2 expression and activity in human aortic smooth muscle cells

European Journal of Pharmacology

Volumn 606, Issue 1-3, 2009, Pages 121-129

  Rival, Yves ^a   Puech, Laurence ^a   Taillandier, Thierry ^a   Benéteau, Nathalie ^a   Rouquette, Anne ^a   Lestienne, Fabrice ^a   Dupont Passelaigue, Elisabeth ^a   Le Roy, Isabelle ^a   Patoiseau, Jean François ^a   Junquéro, Didier ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Atherosclerosis; COX; Inflammation; PPAR (peroxisome proliferator activated receptor); Smooth muscle cell

Indexed keywords

2,2 DICHLORO 12 (4 CHLOROPHENYL)DODECANOIC ACID; 3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; 3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; 6 OXOPROSTAGLANDIN F1 ALPHA; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ALITRETINOIN; CELECOXIB; CELL NUCLEUS RECEPTOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; FARNESOID X RECEPTOR; FENOFIBRIC ACID; INDOMETACIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIVER X RECEPTOR ALPHA; MURAGLITAZAR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; PIRINIXIC ACID; PROSTANOID; RETINOID X RECEPTOR ALPHA; ROFECOXIB; ROSIGLITAZONE; TESAGLITAZAR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL VIABILITY; ENZYME INHIBITION; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; INFLAMMATORY CELL; METABOLIC DISORDER; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; SMOOTH MUSCLE FIBER;

6-KETOPROSTAGLANDIN F1 ALPHA; ANIMALS; AORTA; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; MYOCYTES, SMOOTH MUSCLE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RNA, MESSENGER; SUBSTRATE SPECIFICITY;

EID: 61349106505     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.01.010     Document Type: Article

References (59)

1. Ai-Wen W., Jin G., Zhen-Fu L., Jia-Fu J., and Guang-Wie X. COX-2 expression and tumor angiogenesis in colorectal cancer. World J. Gastroenterol. 10 (2004) 2323-2326
2. Ali F.Y., Davidson S.J., Moraes L.A., Traves S.L., Paul-Clark M., Bishop-Bailey D., Warner T.D., and Mitchell J.A. Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARδ. FASEB J. 20 (2006) 326-328
3. Antonio V., Janvier B., Brouillet A., Andreani M., and Raymondjean M. Oxysterol and 9-cis-retinoic acid stimulate the group IIA secretory phospholipase A2 gene in rat smooth-muscle cells. Biochem. J. 376 (2003) 351-360
4. Barbier O., Torra P., Duguay Y., Blanquart C., Fruchart J.C., Glineur C., and Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 717-726
5. Barish G.D., Narkar V.A., and Evans R.M. PPARδ: a dagger in the heart of the metabolic syndrome. J. Clin. Invest. 116 (2006) 590-597
6. Bishop-Bailey D., Pepper J.R., Larkin S.W., and Mitchell J.A. Differential induction of cyclooxygenase-2 in human arterial and venous smooth muscle. Role of endogenous prostanoids. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1655-1661
7. Bourcier T., Sukhova G., and Libby P. The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J. Biol. Chem. 272 (1997) 15817-15824
8. Browatzki M., Schmidt J., Kubler W., and Kranzhofer R. Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-kappaB in human vascular smooth muscle cells. Bas. Res. Cardiol. 95 (2000) 98-105
9. Bruemmer D., and Law R.E. Liver X receptors: potential novel targets in cardiovascular diseases. Curr. Drug Targets Cardiovasc. Haematol. Disord. 5 (2005) 533-540
10. Burleigh M.E., Babaev V.R., Oates J.A., Harris R.C., Gautam S., Riendeau D., Marnett L.J., Morrow J.D., Fazio S., and Linton M.F. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circ. Res. 105 (2002) 1816-1823
11. Calkin A.C., Allen T.J., Lassila M., Tikellis C., Jandeleit-Dahm K.A., and Thomas M.C. Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse. Atheroscler. 195 (2007) 17-22
12. Chan C.C., Boyce S., Brideau C., Charleson S., Cromlish W., Ethier D., Evans J., Ford-Hutchinson A.W., Forrest M.J., Gauthier J.Y., Gordon R., Gresser M., Guay J., Kargman S., Kennedy B., Leblanc Y., Leger S., Mancini J., O'Neill G.P., Ouellet M., Patrick D., Percival M.D., Perrier H., Prasit P., Rodger I., Tagari P., Therien M., Vickers P., Visco D., Wang Z., Webb J., Wong E., Xu L.J., Young R.N., Zamboni R., and Riendeau D. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J. Pharmacol. Exp. Ther. 290 (1999) 551-560
13. Chawla A., Boisvert W.A., Lee C.H., Laffitte B.A., Barak Y., Joseph S.B., Liao D., Nagy L., Edwards P.A., Curtiss L.K., Evans R.M., and Tontonoz P. A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell. 7 (2001) 161-171
14. Chinetti G., Lestavel S., Bocher V., Remaley A.T., Neve B., Pineda Torra I., Teissier E., Minnich A., Jaye M., Duverger N., Brewer H.B., Fruchart J.C., Clavey V., and Staels B. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of ABCA1 pathway. Nat. Med. 7 (2001) 53-58
15. Chira E.C., McMillen T.S., Wang S., Haw III A., O'Brien K.D., Wight T.N., and Chait A. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice. Atheroscler. 195 (2007) 100-109
16. Claudel T., Leibowitz M.D., Fiévet C., Tailleux A., Wagner B., Repa J.J., Torpier G., Lobaccaro J.M., Paterniti J.R., Mangelsdorf D.J., Heyman R.A., and Auwerx J. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. PNAS 98 (2001) 2610-2615
17. -/- mice. J. Cardiovasc. Pharmacol. 23 (2008) [Electronic publication]
18. Das U.N. COX-2 inhibitors and metabolism of essential fatty acids. Med. Sci. Monit. 11 (2005) RA233-RA237
19. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., Fruchart J.C., Tedgui A., Haegeman G., and Staels B. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J. Biol. Chem. 274 (1999) 32048-32054
20. De Leval X., Delarge J., Devel P., Neven P., Michaux C., Masereel B., Pirotte B., David J.L., Henrotin Y., and Dogne J.M. Evaluation of classical NSAIDs and COX-2 selective inhibitors on purified ovine enzymes and human whole blood. Prostaglandins leukot. essent. 64 (2001) 211-216
21. Delvecchio C.J., Bilan P., Radford K., Stephen J., Trigatti B.L., Cox G., Parameswaran K., and Capone J.P. Liver X receptor stimulates cholesterol efflux and inhibits expression of proinflammatory mediators in human airway smooth muscle cells. Mol. Endocrinol. 21 (2007) 1324-1334
22. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefèvre P.J., Murray G.D., Standl E., Wilcox R.G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R.J., Koranyi L., Laakso M., Mokan M., Norkus A., Pirags V., Podar T., Scheen A., Schernaum W., Schernthaner G., Schmitz O., Skrha J., Smith U., Taton J., and PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
23. Eberhardt W., Akool e.-S., Rebhan J., Frank S., Beck K.F., Franzen R., Hamada F.M., and Pfeilschifter J. Inhibition of cytokine-induced matrix metalloproteinase 9 expression by peroxisome proliferator-activated receptor alpha agonists is indirect and due to a NO-mediated reduction of mRNA stability. J. Biol. Chem. 277 (2002) 33518-33528
24. Eligini S., Barbieri S.S., Cavalca V., Camera M., Brambilla M., De Franceschi M., Tremoli E., and Colli S. Diversity and similarity in signaling events leading to rapid Cox-2 induction by tumor necrosis factor-α and ester in human endothelial cells. Cardiovasc. Res. 65 (2005) 683-693
25. Englesbe M.J., Deou J., Bourns B.D., Clowes A.W., and Daum G. Interleukin-1 beta inhibits PDGF-BB-induced migration by cooperating with PDGF-BB to induce cyclooxygenase-2 expression in baboon aortic smooth muscle cells. J. Vasc. Surg. 39 (2004) 1091-1096
26. Fitzgerald G.A. Coxibs and cardiovascular disease. N. Engl. J. Med. 351 (2004) 1709-1711
27. Gierse J.K., McDonald J.J., Hauser S.D., Rangwala S.H., Koboldt C.M., and Seibert K. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J. Biol. Chem. 271 (1996) 15810-15814
28. Gross B.S., Fruchart J.-C., and Staels B. Peroxisome proliferator-activated receptor β/δ: a novel target for the reduction of atherosclerosis. Drug Discov. Today Therapeut. Strateg. 2 (2005) 237-243
29. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., and Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
30. Kersten S., Desvergne B., and Wahli W. Roles of PPARs in health and disease. Nat 405 (2000) 421-424
31. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glasziou P., Drury P., Kesäniemi Y.A., Sullivan D., Hunt D., Colman P., d, Emden M., Whiting M., Ehnholm C., Laakso M., and FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2006) 1849-1861
32. Libby P., and Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am. J. Cardiol. 99 (2007) 27B-40B
33. Loppnow H., and Libby P. Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J. Clin. Invest. 85 (1990) 731-738
34. Lu T.T., Makishima M., Repa J.J., Schoonjans K., Kerr T.A., Auwerx J., and Mangelsdorf D.J. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Moll. Cell. 6 (2000) 507-515
35. Mach F., Schonbeck U., Sukhova G.K., Bourcier T., Bonnefoy J.Y., Pober J.S., and Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signalling in atherosclerosis. PNAS 94 (1997) 1931-1936
36. Mamdani M., Juurlink D.N., Kopp A., Naglie G., Austin P.C., and Laupacis A. Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. BMJ 328 (2004) 1415-1416
37. Marx N., Schönbeck U., Lazar M.A., Libby P., and Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res. 83 (1998) 1097-1103
38. Marx N., Froehlich J., Siam L., Ittner J., Wierse G., Schmidt A., Scharnagl H., Hombach V., and Koenig W. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetics patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 283-288
39. Marx N., Duez H., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res. 94 (2004) 1168-1178
40. Mukherjee D., Nissen S.E., and Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286 (2001) 954-959
41. Niederberger E., Manderscheid C., Grösch S., Schmidt H., Ehnet C., and Geisslinger G. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem. Pharmacol. 68 (2004) 341-350
42. Oliver W.R., Shenk J.L., Snaith M.R., Russell C.S., Plunket K.D., Bodkin N.L., Lewis M.C., Winegar D.A., Sznaidman M.L., Lambert M.H., Xu H.E., Sternbach D.D., Kliewer S.A., Hansen B.C., and Willson T.M. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. PNAS 98 (2001) 5306-5311
43. Papadaki M., Tilton R.G., Eskin S.G., and McIntire L.V. Nitric oxide production by cultured human aortic smooth muscle cells: stimulation by fluid flow. Am. J. Physiol. 274 (1998) H616-H626
44. Peterson S.J., Drummond G., Kim D.H., Li M., Kruger A.L., Ikehara S., and Abraham N.G. L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice. J. Lipid Res. 49 (2008) 1658-1669
45. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucl. Ac. Res. 29 (2001) 2002-2007
46. Reginato M.J., and Lazar M.A. Mechanisms by which thiazolidinediones enhance insulin action. Trends Endocrinol. Metab. 10 (1999) 9-13
47. Rival Y., Beneteau N., Taillandier T., Pezet M., Dupont-Passelaigue E., Patoiseau J.-F., Junquero D., Colpaert F.C., and Delhon A. PPARα and PPARδ activators inhibit cytokine-induced nuclear translocation of NF-κB and expression of VCAM-1 in EAhy926 endothelial cells. Eur. J. Pharmacol. 435 (2002) 143-151
48. Ryoo S., Won M., Kim D.-U., Kim L., Han G., Park S.-K., Mukaida N., Maeng P., Yoo H.-S., and Hoe K.-L. PPARα activation abolishes LDL-stimulated IL-8 production via AP-1 deactivation in human aortic smooth muscle cells. Biochem. Bioph. Res. Co. 318 (2004) 329-334
49. Schildknecht S., Bachscchmid M., Baumann A., and Ullrich V. COX-2 inhibitors selectively block prostacyclin synthesis in endotoxin exposed vascular smooth muscle cells. FASEB J 10 (2004) 1096
50. Solomon D.H., Schneeweiss S., Levin R., and Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension 44 (2004) 140-145
51. Staels B., Koenig W., Habib A., Merval R., Lebret M., Pineda Torra I., Delerive P., Fadel A., Chinetti G., Fruchart J.C., Najib J., Maclouf J., and Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nat 393 (1998) 790-793
52. Wahli W. Peroxisome proliferator-activated receptors (PPARs): from metabolic control to epidermal wound healing. Swiss Med. Wkly. 132 (2002) 83-91
53. Wang Y.X., Lee C.H., Tiep S., Yu T.Y., Ham J., Kang H., and Evans R.M. Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 113 (2003) 159-170
54. Wang K., Zhou Z., Zhang M., Fan L., Forudi F., Zhou X., Qu W., Lincoff M., Schmidt A.M., Topol E.J., and Penn M.S. Peroxisome proliferator-activated receptor γ down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J. Pharmacol. Exp. Ther. 317 (2006) 37-43
55. Willson T.M., Brown P.J., Sternbach D.D., and Henke B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43 (2000) 527-550
56. Yan Z., Subbaramaiah K., Camilli T., Zhang F., Tanabe T., McCaffrey T.A., Dannenberg A.J., and Weksler B.B. Benzo[a] pyrene induces the transcription of cyclooxygenase-2 in vascular smooth muscle cells. J. Biol. Chem. 275 (2000) 4949-4955
57. Yoyo T.Y.L., Swales K.E., Thomas G.J., Warner T.D., and Bishop-Bailey D. Farnesoid X receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 2606-2611
58. Yudkin J.S., Kumari M., Humphries S.E., and Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atheroscler. 148 (2000) 209-214
59. Zahradka P., Wright B., Fuerst M., Yurkova N., Molnar K., and Taylor C.G. Peroxisome proliferator-activated receptor α and γ ligands differentially affect smooth muscle cell proliferation and migration. J. Pharmacol. Exp. Ther. 317 (2006) 651-659